Prime Medicine PRME

Prime Medicine, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

$5.36+23.22%close on Oct. 28, 2026 · volume 15.2M · Yahoo Finance

Price, last 47 sessions

Aug. 24, 2026 to Oct. 28, 2026 · high $5.36 · low $2.88

Nothing published yet.

No open-market insider buying or selling in the Form 4s filed since July 24, 2026.

10-QAug. 6, 2026, 8:03 a.m. ETView on SEC.gov
8-KAug. 6, 2026, 8:02 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits

Market cap

$972.2 million

$5.36 x shares as of July 31, 2026

Revenue, quarter

$0.8 million

ended Dec. 31, 2025 (Q4 derived); year earlier $2.2 million

Revenue, fiscal year

$4.6 million

ended Dec. 31, 2025; prior $3.0 million

Net income, quarter

-$42.1 million

ended June 30, 2026; year earlier -$52.6 million

Net income, fiscal year

-$201.1 million

ended Dec. 31, 2025; prior -$195.9 million

Operating income, quarter

-$43.3 million

ended June 30, 2026; year earlier -$53.4 million

Operating income, fiscal year

-$208.3 million

ended Dec. 31, 2025; prior -$202.5 million

Diluted EPS, quarter

-$0.24

ended June 30, 2026; year earlier -$0.41

Diluted EPS, fiscal year

-$1.35

ended Dec. 31, 2025; prior -$1.65

Cash and equivalents

$47.5 million

as of June 30, 2026

From the company's SEC filings (XBRL). Market cap uses the latest cover-page share count.

Date	Firm	Rating	Target
Sept. 25, 2026	Chardan Capital	Buy	$7.00
Aug. 25, 2026	Chardan Capital	Buy	$7.00
Aug. 19, 2026	BMO Capital	Outperform	$9.00
Aug. 10, 2026	HC Wainwright & Co.	Buy	$8.00
June 29, 2026	HC Wainwright & Co.	Neutral → Buy	$8.00
March 12, 2026	Oppenheimer	Outperform	$11.00
Dec. 23, 2025	LifeSci Capital	Outperform	$6.00
Nov. 11, 2025	Citigroup	Neutral	$4.25
Nov. 10, 2025	Chardan Capital	Buy	$9.00

Source: Yahoo Finance. Dates are UTC.